Literature DB >> 16803567

Clearance of leukaemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukaemia: a pilot study.

Giacomo Gianfaldoni1, Francesco Mannelli, Michela Baccini, Elisabetta Antonioli, Franco Leoni, Alberto Bosi.   

Abstract

Although several parameters are useful for risk stratification of patients with acute myeloid leukaemia (AML), there are no firm criteria for predicting response to induction treatment of individual patients. Daily flow cytometry (FC) analysis, carried out during induction treatment in 30 AML patients, showed that the clearance of blasts from peripheral blood (PBC) correlated closely with response, as assessed by bone marrow FC on day 14, and by morphologic analysis at haematopoietic recovery. Therefore, a major treatment outcome can be predicted very early in AML patients, thus providing an opportunity for tailoring treatment modalities from the outset.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16803567     DOI: 10.1111/j.1365-2141.2006.06100.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  13 in total

1.  Rapid rate of peripheral blood blast clearance accurately predicts complete remission in acute myeloid leukemia.

Authors:  V Vainstein; S A Buckley; O Shukron; E H Estey; J L Abkowitz; B L Wood; R B Walter
Journal:  Leukemia       Date:  2013-11-18       Impact factor: 11.528

Review 2.  Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia.

Authors:  Mary-Elizabeth Percival; Catherine Lai; Elihu Estey; Christopher S Hourigan
Journal:  Blood Rev       Date:  2017-02-02       Impact factor: 8.250

Review 3.  Minimal residual disease in acute myelogenous leukemia.

Authors:  N M Cruz; N Mencia-Trinchant; D C Hassane; M L Guzman
Journal:  Int J Lab Hematol       Date:  2017-05       Impact factor: 2.877

4.  Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group.

Authors:  Jacob M Rowe; Haesook T Kim; Peter A Cassileth; Hillard M Lazarus; Mark R Litzow; Peter H Wiernik; Martin S Tallman
Journal:  Cancer       Date:  2010-11-01       Impact factor: 6.860

5.  Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy.

Authors:  Nicholas J Short; Christopher B Benton; Hsiang-Chun Chen; Peng Qiu; Lisa Gu; Sherry Pierce; Mark Brandt; Abhishek Maiti; Taejin L Min; Kiran Naqvi; Alfonso Quintas-Cardama; Marina Konopleva; Tapan Kadia; Jorge Cortes; Guillermo Garcia-Manero; Farhad Ravandi; Elias Jabbour; Hagop Kantarjian; Michael Andreeff
Journal:  Am J Hematol       Date:  2016-08-29       Impact factor: 10.047

Review 6.  New approaches for the detection of minimal residual disease in acute myeloid leukemia.

Authors:  Anna van Rhenen; Bijan Moshaver; Gert J Ossenkoppele; Gerrit Jan Schuurhuis
Journal:  Curr Hematol Malig Rep       Date:  2007-05       Impact factor: 3.952

7.  Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission.

Authors:  Roland B Walter; Brenda M Sandmaier; Barry E Storer; Colin D Godwin; Sarah A Buckley; John M Pagel; Mohamed L Sorror; H Joachim Deeg; Rainer Storb; Frederick R Appelbaum
Journal:  Biol Blood Marrow Transplant       Date:  2014-09-30       Impact factor: 5.742

8.  Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial.

Authors:  Giacomo Gianfaldoni; Francesco Mannelli; Tamara Intermesoli; Sara Bencini; Damiano Giupponi; Giorgio Farina; Ilaria Cutini; Maria Ida Bonetti; Arianna Masciulli; Ernesta Audisio; Dario Ferrero; Chiara Pavoni; Anna Maria Scattolin; Alberto Bosi; Alessandro Rambaldi; Renato Bassan
Journal:  Blood Adv       Date:  2020-01-28

Review 9.  Is minimal residual disease monitoring clinically relevant in adults with acute myelogenous leukemia?

Authors:  Karen-Sue B Carlson; Monica L Guzman
Journal:  Curr Hematol Malig Rep       Date:  2013-06       Impact factor: 3.952

10.  Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia.

Authors:  Giacomo Gianfaldoni; Francesco Mannelli; Vanessa Ponziani; Giovanni Longo; Sara Bencini; Alberto Bosi; Alessandro M Vannucchi
Journal:  Haematologica       Date:  2010-01-27       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.